Skip to main content

Table 2

From: Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence

Exon/Variant

Genotype

Level of adverse effects

P-value

  

0

1

2

3

 

a)

      

Pleural thickening

Exon 20

GG

136

82

23

1

0.001

IVS20+28delG

GA

4

2

0

1

 

Exon 31, rs1800058

CC

135

82

23

1

> 0.001

4258 C>T

CT

5

1

0

1

 

Leu > Phe

      

Exon 41, rs3092910

      

5793 T>C

TT

136

82

23

1

0.001

Ala > Ala

TC

4

2

0

1

 

Lung fibrosis

Exon 31, rs1800058

CC

66

156

18

1

> 0.001

4258 C>T

CT

3

3

0

1

 

Leu > Phe

      

Development of telangiectasias

Exon 39, rs1801516

GG

35

33

41

70

0.042

5557 G>A

GA

11

14

10

20

 

Asp > Asn

AA

4

1

0

0

 

Atrophy

Exon 31, rs1800058

      

4258 C>T

CC

35

57

74

65

0.02

Leu > Phe

CT

4

1

0

2

 

b)

      

Pleural thickening

Exon 20

GG

69

61

19

0

> 0.001

IVS20+28delG

GA

2

2

0

1

 

Exon 41, rs3092910

TT

69

61

19

0

> 0.001

5793 T>C

TC

2

2

0

1

 

Ala > Ala

      

Lung fibrosis

Exon 32, rs1800889

CC

11

111

13

0

0.009

4578 C>T

CT

4

11

2

1

 

Pro > Pro

      

Development of telangiectasias

Exon 39, rs1801516

GG

14

21

28

47

0.027

5557 G>A

GA

4

9

9

15

 

Asp > Asn

AA

3

1

0

0

 

c)

      

Costal fractures

Exon 9, rs3218674

CC

75

12

1

0

0.043

735 C>T

CT

6

0

1

0

 

Val > Val

      

Pleural thickening

Exon 31, rs1800058

CC

64

20

4

0

0.001

4258 C>T

CT

5

0

0

1

 

Leu > Phe

      

Lung fibrosis

Exon 31, rs1800058

CC

51

35

2

0

0.002

4258 C>T

CT

3

2

0

1

 

Leu > Phe

      

Subcutaneous fibrosis

Exon 32, rs1800889

CC

32

25

16

5

0.022

4578 C>T

CT

6

1

0

3

 

Pro > Pro

      
  1. Associations of genetic variance in the ATM gene with radiation induced side effects in the Norwegian breast cancer patients: for all patients combined (a), treatment A (4.3 Gy *10, b) and treatment B (2.5 Gy *25, c) (organized by adverse effect, level of adverse effect is divided into four groups: none (0), little (1), some (2) and substantial (3)). (The P-values are not adjusted for multiple testing)